Updated on 25 August 2025
A breakthrough therapy project for the treatment of neurodegeneration to unlock a $60B+ market
About
SunRegen is a Swiss biopharmaceutical pioneer developing the world’s first oral neuro-rescuing therapy with the potential to treat retinal and CNS neurodegenerative diseases. Backed by Nobel-recognized science, robust preclinical data, and a $60B+ market opportunity, SBC003 represents a rare investment opportunity to support a first-in-class therapy with super blockbuster potential.
Project Location
- Switzerland
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Health Technology
Total Project Value
- 50,000,001 USD or above
Investment Capital Required
- 10,000,001 to 25,000,000 USD
Interested Format of Cooperation
- Joint Venture
- Open for Negotiation
- R&D Cooperation
Preferred Financing Model
- Equity
- Open for negotiation
Previous Funding Stage
- Seed & Pre-Series
Return on Investment
200
Main Service(s) Required
- Professional Services
Attached files
Organisation
Reinach, Switzerland
Similar opportunities
Project
Peptide (Peptide API/Intermediate/CDMO) Project多肽(多肽原料药/中间体/CDMO)项目
- No
- None
- Technology
- Health Facilities
- Medical Technology
- Financial Services
- Open for Negotiation
- Open for negotiation
- 50,000,001 USD or above
- Feasibility Study Completed
- 10,000,001 to 25,000,000 USD
- Public-Private Partnership Project
- Public–private partnership / Concession
chaoyou wang
Chairman at Dongchao Technology Group
Shanghai, China
Project
- No
- None
- Equity
- Operations
- Manufacturing
- Private Project
- Financial Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- 7,500,001 to 10,000,000 USD
- 10,000,001 to 25,000,000 USD
Mark Harrison
CEO and Founder at Wealth Matrix
London, United Kingdom
Project
AI & MAPIS Enable Portable Non-Invasive Blood Glucose Monitoring
- No
- None
- Technology
- Joint Venture
- Private Project
- R&D Cooperation
- Health Technology
- Financial Services
- Open for Negotiation
- Open for negotiation
- Minority Shareholdings
- Feasibility Study Completed
- 10,000,001 to 25,000,000 USD
- 10,000,001 to 25,000,000 USD
Ryan Jing
CEO at TechInu Inc.
Toronto, Canada